Radotinib to take on Gleevec, Sprycel

Radotinib is Korea’s 18th homegrown leukemia drug and the world’s fifth and was approved by the Korea Food and Drug Administration on January 4.

Market watchers say the new drug is likely to bring a huge change to the anti-leukemia medicine market, as patients here have had access to only imported drugs costing 70 to 100 billion won per year. There are about 2,300 chronic myeloid leukemia pa...